Rhumbline Advisers Grows Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Rhumbline Advisers grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 458.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 430,062 shares of the company's stock after buying an additional 352,994 shares during the period. Rhumbline Advisers owned 0.05% of Dr. Reddy's Laboratories worth $6,791,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Dr. Reddy's Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock valued at $36,000 after buying an additional 137 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy's Laboratories during the third quarter valued at about $60,000. Van ECK Associates Corp increased its position in shares of Dr. Reddy's Laboratories by 64.3% during the third quarter. Van ECK Associates Corp now owns 823 shares of the company's stock valued at $64,000 after buying an additional 322 shares during the period. POM Investment Strategies LLC increased its position in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the period. Finally, Glenmede Trust Co. NA bought a new stake in shares of Dr. Reddy's Laboratories during the third quarter valued at about $207,000. 3.85% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Finally, Barclays decreased their price objective on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy's Laboratories Price Performance

Shares of RDY stock traded down $0.19 during trading on Friday, hitting $12.77. The company had a trading volume of 2,509,408 shares, compared to its average volume of 2,028,354. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock's 50-day moving average is $14.51 and its two-hundred day moving average is $15.10. The stock has a market capitalization of $10.66 billion, a price-to-earnings ratio of 20.33 and a beta of 0.50. Dr. Reddy's Laboratories Limited has a 52 week low of $12.62 and a 52 week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.